- A rapid test designed for preliminary prostate cancer screening
- Simple steps and user-friendly design
- Nanotechnology aid colorimetric-based detection
This product is licensed exclusively to a renowned pharmaceutical company in Hong Kong.
For detailed product information, please kindly contact JACOBSON PHARMA CORPORATION LIMITED via this link: http://www.jacobsonpharma.com/
Conventional prostate cancer screening techniques such as Prostate Specific Antigen (PSA) test and Magnetic resonance imaging (MRI) are either inaccurate, expensive, inconvenient or invasive. With that, we have invented a new technology to support the application of a home-based diagnostic kit, which allows users to measure the risk of prostate cancer accurately at their desirable places. This invention is exclusively licensed to a subsidiary of Jacobson Pharma Corporation Limited (HKEX Stock No. 2633) for product design, manufacturing and commercialization in the global market, the home-based diagnosis kit will be firstly launched in Hong Kong in 2020.